ClinicalTrials.gg
CompletedNCT03481998Updated Nov 21, 2023

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A Phase 1/2 interventional study of SHR6390 and Letrozole or anastrozole or Fulvestrant in Advanced Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 4 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 49 studies testing dalpiciclib in Breast Neoplasms — 30 open to participants now, 35 under way, 4 of them phase 3. dalpiciclib · Breast Neoplasms.

Enrollment
21st of 49
104 · median 72
Started
2018
the only one that year
Phase 1/2
4 of 49
none open now
Registered
1st of 49
by date
Lead sponsor
5 of 49
Jiangsu HengRui Medicine Co., Ltd.

Among the 49 studies testing dalpiciclib in Breast Neoplasms, this one is the 21st largest by enrollment, is the only one that started in 2018, is one of 4 in phase 1/2, and was the 1st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 49 studies testing dalpiciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

About dalpiciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing dalpiciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • CDK4/6 inhibitor
  • Breast cancer
  • Postmenopausal women
  • Hormone-receptor positive
  • HER2 negative
  • Premenopausal women
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Has the -confirmed diagnosis of locally recurrent or , hormone-receptor positive, negative Breast Cancer.
  2. Age: 18 - 75 years old, women.prepostmenopausal women, but should receive Ovary castration.

    Inclusion Criteria

  3. Cohort 1 and Cohort 2 :No prior systemic anti-cancer therapy for advanced HR+ disease.

Cohort 3 and Cohort 4 : Patients must satisfy the following criteria for prior therapy:

  1. a) Progressed after 2 years during treatment of therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.

    b)Progressed within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre- or perimenopausal.

    c) Progressed while 6 month after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer if postmenopausal, or prior endocrine treatment for advanced/metastatic breast cancer if pre- or perimenopausal.

  2. One for advanced/metastatic disease is allowed in addition to endocrine therapy.
  1. [ECOG] 0-1 as per Response Evaluation Criterion in Solid Tumors[] 1.1
  1. Adequate organ and marrow function

Exclusion Criteria

  1. Confirmed diagnosis of HER2 positive disease
  2. Patients who received any endocrine therapy as neo/adjuvant therapy for breast cancer are eligible. If the neo/adjuvant therapy of any endocrine therapy , the disease-free interval must be greater than 12 months from the completion of treatment until study entry.
  3. Patients who received prior treatment with any CDK4/6 inhibitor, everolimus,fulvestant.
  4. cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure ( (NYHA) class > 2), or ventricular arrhythmia which need medical intervention.
  5. Has known active central nervous system metastases.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Part 1)

    Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).

    Drug: SHR6390 · Drug: Letrozole or anastrozole or Fulvestrant

  • Experimental
    Cohort 2 (Part 1)

    SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).

    Drug: SHR6390 · Drug: Letrozole or anastrozole or Fulvestrant

  • Experimental
    SHR6390 + Letrozole or anastrozole (Part 2)

    SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).

    Drug: SHR6390 · Drug: Letrozole or anastrozole or Fulvestrant

  • Experimental
    SHR6390 + Fulvestrant Cohort 3 (Part 1)

    SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily

    Drug: SHR6390 · Drug: Letrozole or anastrozole or Fulvestrant

  • Experimental
    SHR6390 + Fulvestrant Cohort 4 (Part 1)

    SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily

    Drug: SHR6390 · Drug: Letrozole or anastrozole or Fulvestrant

Interventions

  • SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • DrugLetrozole or anastrozole or Fulvestrant

    Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously), or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

This study also gives Fulvestrant, Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1

    Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03. Up to 24 months.

    Time frame: Up to 4 weeks

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC) of SHR6390

    Time frame: Up to 4 weeks

  2. Peak Plasma Concentration (Cmax) of SHR6390

    Time frame: Up to 4 weeks

  3. The time of SHR6390 to reach the maximum concentration (Tmax)

    Time frame: Up to 4 weeks

  4. Half-time (t1/2) of SHR6390

    Time frame: Up to 4 weeks

  5. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ¡Ý30% decrease in the sum of diameters of target lesions) per RECIST 1.1.

    Time frame: Up to approximately 24 months.

  6. Progression-free Survival (PFS) per RECIST 1.1

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months.

  7. Disease Control Rate (DCR) per RECIST 1.1

    DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.

    Time frame: Up to approximately 24 months.

  8. Number of Participants With adverse events (AEs) and serious adverse events (SAEs)

    Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.03.

    Time frame: Up to approximately 24 months.

07

Study locations

4 sites
  • Ha'erbin Tumor Hospital
    Ha'erbin, Heilongjiang, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Sir Run Run Shaw Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jul 2022, 52 months.

Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 52 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2018
First posted
Mar 29, 2018
StartActual
Mar 22, 2018
Primary completionActual
Jul 30, 2022
CompletionActual
Jul 30, 2022
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03481998
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Mar 22, 2018
Primary completion
Jul 30, 2022
Completion
Jul 30, 2022
Last update
Nov 21, 2023

Study contacts

Binhe Xu, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalpiciclib

Start the discussion